WATERTOWN, Mass.--(BUSINESS WIRE)--1CellBio, Inc., today announced a new program to supply select customers with its proprietary inDrop™ hydrogel beads synthesized with custom primers that target user-specified transcripts.
“This new program enables researchers to focus their sequencing depth on their genes of interest rather than the full transcriptome,” said Colin J.H. Brenan, PhD, Chief Executive Officer at 1CellBio. “We believe the ability to customize and target transcriptional regions of interest will accelerate clinical and pharmaceutical research applications of single-cell RNA-seq.”
The inDrop technology enables researchers to run full transcriptomic analysis with single cells. Rather than binding the full spectrum of mRNAs, this new program provides custom targeted beads to capture transcripts of a very specific set of user-selected genes within single cells. Some of the potential applications for the targeted beads might be custom oncogene panels, immunoprofiling for antibodies and T-cell receptors, or mRNA isoform detection.
“Using the inDrop whole-transcriptome approach, our customers are discovering key genes that are differentially expressed between cell types. This program will broaden the technology to develop new applications by providing specific DNA oligonucleotides on inDrop hydrogel beads,” said Mike Kopczynski, Chief Operating Officer at 1CellBio. “Custom panels for targeted transcript capture are the natural next phase in single-cell analysis.”
About 1CellBio
1CellBio Inc. is a leading single-cell
analysis company serving the biomedical research community. The
company’s flagship inDrop™ System, a high-resolution, single-cell
transcriptomics platform, delivers greater experimental control, rare
actionable information and lower overall cost per result compared to all
other existing platforms. Research laboratories around the world are now
adopting the platform for a wide range of single-cell applications from
tumor profiling to stem cells to embryo development to the
identification and validation of new drug targets. Founded by a group of
prominent scientists at Harvard University, 1CellBio is based in
Watertown, Mass., and the company supports its growing number of
customers through a team of international sales and field application
scientists. For more information, please visit www.1cell-bio.com.
